Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy

AIDS

Volumn 18, Issue 4, 2004, Pages

  Brumme, Zabrina L ^a,b   Dong, Winnie W Y ^a   Yip, Benita ^a   Wynhoven, Brian ^a   Hoffman, Noah G ^c   Swanstrom, Ronald ^c   Jensen, Mark A ^d   Mullins, James I ^d   Hogg, Robert S ^a,b   Montaner, Julio S G ^a,b   Harrigan, P Richard ^a,b,e  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

11 25 genotype; Antiretroviral therapy response; HAART; HIV; HOMER cohort; Neural network; PSSM; V3 loop

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NERVE CELL NETWORK; NUCLEOTIDE SEQUENCE; PHENOTYPE; PLASMA; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEURAL NETWORKS (COMPUTER); PEPTIDE FRAGMENTS; PHENOTYPE; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VARIATION (GENETICS); VIRAL LOAD;

EID: 12144291059     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200403050-00001     Document Type: Article

References (31)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
2. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Can Med Assoc J 1999, 160:659-665.
3. Wainberg MA, Friedland G. Public Health implications of antiretroviral therapy and HIV drug resistance. JAMA 1999, 279:1977-1983.
4. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222-235.
5. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
6. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
7. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003, 17:711-720.
8. Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, Schellekens PT, et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 1989, 63:2118-2125.
9. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell tropic virus populations. J Virol 1992, 66:1354-1360.
10. Koot M, Keet IP, Vos AH. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Int Med 1993, 118:681-688.
11. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994, 169:968-974.
12. Rusconi S, De Pasquale MP, Mainini F, Bulgheroni E, Kurtagic S, Gori A, et al. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people. Antivir Ther 1996, 1:211-219.
13. Katzenstein TL, Nielsen C, Bruun L, Mathiesen LR, Pedersen C, Gerstoft J. Quantification of HIV-1 RNA during antiretroviral therapy: association with viral phenotype and development of resistance. Antivir Ther 1996, 1:246-254.
14. Vidal C, Garcia F, Gatell JM, Leal M, Clotet B, Pumarola T, et al. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:55-60.
15. Davey RT Jr, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, et al. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1996, 40: 1657-1664.
16. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997, 126:929-938.
17. Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandstrom E. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 1998, 12:2193-2202.
18. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997, 71:7478-7487.
19. Fouchier RA, Brouwer M, Broersen SM, Schuitemaker H. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol 1995, 33:906-911.
20. O'Brien WA, Koyanagi Y, Namazie A, Zhao JQ, Diagne A, Idler K, et al. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 1990, 348:69-73.
21. Shioda T, Levy JA, Cheng-Mayer C. Macrophage and T cell line-tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 1991, 349:167-169.
22. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992, 66:6777-6780.
23. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, et al. Phenotype-associated sequence variation of the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992, 66:3183-3187.
24. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swanstrom R. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 2002, 76:3852-3864.
25. Resch W, Hoffman N, Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001, 288:51-62.
26. Jensen MA, van't Wout A. Predicting HIV-1 co-receptor usage using sequence analysis. AIDS rev 2003, 5:104-112.
27. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000, 283:2417-2426.
28. Alexander CS, Dong W, Chan K, Jahnke N, O'Shaughnessy MV, Mo T, et al. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naïve individuals from a large North American cohort. AIDS 2001, 15:601-607.
29. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, et al. Drug resistance mutations in HIV-1. Topics HIV Med 2002, 10:21-25.
30. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow up. AIDS 2002, 16:1051-1058.
31. Pillai S, Good B, Richman D, Corbeil J. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003, 19:145-149.